BRAF V600D Inhibitors
1 drugsAbout BRAF V600D
BRAF V600D is a mutated form of the BRAF protein, a key signaling molecule in the RAS/MAPK pathway that controls cell growth and differentiation. Its constitutive activation drives uncontrolled cell proliferation, making it an important target in oncology.
The rationale for targeting BRAF V600D stems from its prevalence in various cancers. However, there is currently no genetic evidence directly linking BRAF V600D to specific diseases in this dataset.
There is one FDA-approved drug, TAFINLAR (Novartis), targeting BRAF V600D for oncology indications. TAFINLAR, a small molecule, was first approved in 2013.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Advanced Lymphoma with only 2 trials.
- phase1 represents biological uncertainty with 55% completion.
Top BRAF V600D Drugs
Novartis is the only company with an approved drug targeting BRAF V600D.
The lack of competition suggests a high barrier to entry or an untapped market opportunity.
BRAF V600D Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BRAF V600D, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
BRAF V600D Clinical Trials 91 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 33 | 12 | 13 | 7 | 48% |
| Phase 2 | 47 | 14 | 12 | 21 | 54% |
| Phase 3 | 8 | 4 | 1 | 3 | 80% |
| Phase 4 | 3 | 0 | 0 | 3 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
BRAF V600D Drug Approval Timeline (2013 - 2013)
The first and only drug, TAFINLAR, was approved in 2013.
The approval timeline suggests potential saturation, requiring novel approaches for future development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 84 clinical trials targeting BRAF V600D.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities